HOLMES

(one-HOur Low-cost Multipurpose highly Efficient System)

ToloBio first discovered that the CRISPR-Cas12 protein has efficient "trans-cleavage activity" and developed the "HOLMES" (one-HOur Low-cost Multipurpose highly Efficient System) nucleic acid rapid detection platform. CRISPR-Dx have been recognized as "the next-generation molecular diagnostic technology" by SCIENCE journal.

首页大图(2).png
0 %

Shorter Turnaround Time

0 %

Higher Specificity

0 %

Lower Cost

0 %

Higher Sensitivity

首页大图(2).png
gdb_icon1.png
gdw_icon1.png
Virus Detection
gdb_icon2.png
gdw_icon2.png
SNP Discrimination
gdb_icon3.png
gdw_icon3.png
Cancer Screening
gdb_icon4.png
gdw_icon4.png
Antibiotic-resistant
动物-未选中.png
动物-选中.png
Animal Epidemic
gdb_icon5.png
gdw_icon5.png
Bacteria Detection
gdb_icon7.png
gdw_icon7.png
Food Safety Testing
封面.jpg
封面.jpg
封面.jpg
合作伙伴

吐露港生物与美国 SHERLOCK BIOSCIENCES(创始人:张锋)就Cas12和Cas13的诊断技术达成专利交叉授权合作。吐露港生物愿携手创新型IVD企业,加快推进CRISPR诊断产业的蓬勃发展。

sherlock.png Sherlock Biosciences

伯杰.png 伯杰医疗

华大.png 华大基因

源景泰科(1).png 源景泰科

臻准生物(1).png 臻准生物